Select Publications
Book Chapters
2017, 'Multidisciplinary approach to treatment: An Australian perspective', in Sarcoma: A Multidisciplinary Approach to Treatment, Springer, pp. 461 - 476, http://dx.doi.org/10.1007/978-3-319-43121-5_23
,2017, 'Bone Sarcomas in the Adolescent and Young Adult Population', in Bleyer A; Barr R; Ries L; Whelan J; Ferrari A (ed.), Cancer in Adolescents and Young Adults., Springer, pp. 417 - 427, http://dx.doi.org/10.1007/978-3-319-33679-4_16
,2009, 'No-man’s land: Between paediatric and adult medical oncology', in When Cancer Crosses Disciplines: A Physician's Handbook, pp. 885 - 906, http://dx.doi.org/10.1142/9781848163652_0035
,Journal articles
2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4
,2024, 'Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing', Nature Communications, 15, pp. 1818, http://dx.doi.org/10.1038/s41467-024-46001-8
,2024, 'Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma', Cancer Epidemiology, 92, http://dx.doi.org/10.1016/j.canep.2023.102432
,2024, 'From ownership to custodianship of tumor biopsy tissue in genomic testing: A mixed methods study of patient views', Oncologist, 29, pp. e1169 - e1179, http://dx.doi.org/10.1093/oncolo/oyae074
,2024, 'Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development', Cancer Cell, 42, pp. 923 - 929, http://dx.doi.org/10.1016/j.ccell.2024.05.014
,2024, 'Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23–24, 2023', Molecular Oncology, 18, pp. 245 - 279, http://dx.doi.org/10.1002/1878-0261.13575
,2024, 'ASPiRATION: Australian Observational Cohort Study of Comprehensive Genomic Profiling in Metastatic Lung Cancer Tissue', Future Oncology, 20, pp. 361 - 371, http://dx.doi.org/10.2217/fon-2023-0366
,2024, 'Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00453
,2024, 'Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework', Therapeutic Advances in Medical Oncology, 16, http://dx.doi.org/10.1177/17588359241273062
,2024, 'Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans', Genetics in Medicine Open, 2, http://dx.doi.org/10.1016/j.gimo.2024.101895
,2024, 'Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program', Surgery (United States), http://dx.doi.org/10.1016/j.surg.2024.05.058
,2024, 'POT1 clinical risk management is an open question', European Journal of Human Genetics, http://dx.doi.org/10.1038/s41431-024-01676-x
,2024, '623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12', Annals of Oncology, 35, pp. S498 - S498, http://dx.doi.org/10.1016/j.annonc.2024.08.690
,2023, 'A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content', npj Genomic Medicine, 8, http://dx.doi.org/10.1038/s41525-023-00369-6
,2023, 'Precision medicine: affording the successes of science', npj Precision Oncology, 7, http://dx.doi.org/10.1038/s41698-022-00343-y
,2023, 'Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype', Oncogene, 42, pp. 3529 - 3541, http://dx.doi.org/10.1038/s41388-023-02864-7
,2023, 'PATH-25. EXPLORING THE PROGNOSTIC IMPLICATIONS OF MOLECULAR ALTERATIONS IN ASTROCYTOMAS USING COMPREHENSIVE GENOMIC PROFILING (CGP)', Neuro-Oncology, 25, pp. v173 - v173, http://dx.doi.org/10.1093/neuonc/noad179.0655
,2023, 'Modified study designs to expand treatment options in personalised oncology: a multistakeholder view', European Journal of Cancer, 194, http://dx.doi.org/10.1016/j.ejca.2023.113278
,2023, 'Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature', British Journal of Haematology, 203, pp. 481 - 484, http://dx.doi.org/10.1111/bjh.19059
,2023, 'Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials', International Journal of Cancer, 153, pp. 1413 - 1422, http://dx.doi.org/10.1002/ijc.34649
,2023, 'Family communication and results disclosure after germline sequencing: A mixed methods study', Patient Education and Counseling, 114, http://dx.doi.org/10.1016/j.pec.2023.107800
,2023, 'Implementation of the Australasian Teletrial Model: Translating ideas into action using implementation science frameworks', Journal of Telemedicine and Telecare, 29, pp. 641 - 647, http://dx.doi.org/10.1177/1357633X211017805
,2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0
,2023, 'Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.', Journal of Clinical Oncology, 41, pp. 3101 - 3101, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3101
,2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 2594 - 2594, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2594
,2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 41, pp. 4093 - 4093, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4093
,2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.', Journal of Clinical Oncology, 41, pp. 1540 - 1540, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1540
,2023, 'Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.', Journal of Clinical Oncology, 41, pp. 10578 - 10578, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10578
,2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 5526 - 5526, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5526
,2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', Journal of Clinical Oncology, 41, pp. 3127 - 3127, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3127
,2023, 'Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare', American Journal of Human Genetics, 110, pp. 419 - 426, http://dx.doi.org/10.1016/j.ajhg.2023.01.018
,2023, 'Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab', Molecular Oncology, 17, pp. 298 - 311, http://dx.doi.org/10.1002/1878-0261.13349
,2023, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', Science, 379, pp. 253 - 260, http://dx.doi.org/10.1126/science.abj4784
,2022, 'Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients with Cancer: A Narrative Review', JAMA Oncology, 8, pp. 1830 - 1839, http://dx.doi.org/10.1001/jamaoncol.2022.4457
,2022, 'Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers', Asia-Pacific Journal of Clinical Oncology, 18, pp. 660 - 668, http://dx.doi.org/10.1111/ajco.13745
,2022, 'Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-30496-0
,2022, 'Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments', Cancer Treatment Reviews, 110, http://dx.doi.org/10.1016/j.ctrv.2022.102455
,2022, 'Effective and Efficient Delivery of Genome-Based Testing-What Conditions Are Necessary for Health System Readiness?', Healthcare (Switzerland), 10, http://dx.doi.org/10.3390/healthcare10102086
,2022, 'Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study', Supportive Care in Cancer, 30, pp. 8201 - 8210, http://dx.doi.org/10.1007/s00520-022-07272-3
,2022, 'Using whole-genome sequencing to characterize clinically significant blood groups among healthy older Australians', Blood Advances, 6, pp. 4593 - 4604, http://dx.doi.org/10.1182/bloodadvances.2022007505
,2022, 'Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting', European Journal of Human Genetics, 30, pp. 930 - 937, http://dx.doi.org/10.1038/s41431-022-01069-y
,2022, 'Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients', Patient Education and Counseling, 105, pp. 2206 - 2216, http://dx.doi.org/10.1016/j.pec.2022.01.011
,2022, 'Challenges of Conducting Value Assessment for Comprehensive Genomic Profiling', International Journal of Technology Assessment in Health Care, 38, http://dx.doi.org/10.1017/S026646232200040X
,2022, 'Psychological predictors of cancer patients' and their relatives’ attitudes towards the return of genomic sequencing results', European Journal of Medical Genetics, 65, http://dx.doi.org/10.1016/j.ejmg.2022.104516
,2022, 'Unlocking Access to Broad Molecular Profiling: Benefits, Barriers, and Policy Solutions', Public Health Genomics, 25, pp. 70 - 79, http://dx.doi.org/10.1159/000520000
,2022, 'In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer', EMBO Molecular Medicine, 14, pp. emmm202114608, http://dx.doi.org/10.15252/emmm.202114608
,2022, 'Population DNA screening for medically actionable disease risk in adults', Medical Journal of Australia, 216, pp. 278 - 280, http://dx.doi.org/10.5694/mja2.51454
,